PET/MRI Imaging of Glutamate Release in the Brain
Phase 2
Terminated
- Conditions
- Healthy
- Interventions
- Drug: 18F-PSS232
- Registration Number
- NCT02511691
- Lead Sponsor
- University of Zurich
- Brief Summary
Based on PET (18-PSS232) and MRI, glutamate release after N-acetylcystein challenge will be monitored in human brains.
- Detailed Description
Diagnostic trial with quantification of glutamate release in PET/MR.
Recruitment & Eligibility
- Status
- TERMINATED
- Sex
- All
- Target Recruitment
- 10
Inclusion Criteria
- healthy volunteer
Read More
Exclusion Criteria
- smoker
- drug addiction
- significant neurological or psychiatric conditions
Read More
Study & Design
- Study Type
- INTERVENTIONAL
- Study Design
- SINGLE_GROUP
- Arm && Interventions
Group Intervention Description 18F-PSS232 18F-PSS232 Subjects receive baseline PET with 18F-PSS232 and stimulation PET with 18F-PSS232 after medical challenge with N-acetylcystein
- Primary Outcome Measures
Name Time Method Difference of Binding Potentials of 18F-PSS232 in different brain regions between Baseline PET and PET after medical challenge Baseline PET and PET after medical challenge will be scanned within 3 months for details, please see Innis: Journal of Cerebral Blood Flow \& Metabolism (2007) 27, 1533-1539
- Secondary Outcome Measures
Name Time Method
Trial Locations
- Locations (1)
University Hopsital Zurich
🇨ðŸ‡Zurich, Switzerland